NA Proactive news snapshot: Mandalay Resources, Canafarma, FSD Pharma, NetCents

Mandalay Resources Corporation () () on Monday unveiled encouraging exploration drilling results from its mines in Australia and Sweden, which underscore the potential to continue to expand these operations. The metals miner has been carrying out regional testing and resource extension work at the Costerfield mine in Australia and the Björkdal operation in Sweden. Notably, a first hole at the Brown’s prospect, 2.3 km east from the high grade Youle mine at Costerfield, returned a highly significant intersection of 14.5 grams per ton (g.t) gold, over a true width of 1.27 metres (m) and 23.5 g/t gold over 0.12 metres, the firm said.

Hemp Products Corp () announced on Monday that it will launch two new hemp oil-infused chewing gums in July this year. The move expands the hemp-focused group’s flagship YOOFORIC chewing gum brand, under its confectionary line, it said in a statement Monday. YOOFORIC RISE, a chill mint flavor gum, contains a unique blend of full spectrum hemp oil, with naturally occurring CBD, Green Tea, Omega-3 Fatty Acids (DHA and EPA), L-tryptophan, Vitamin B3, Vitamin C, and Magnesium Citrate, the firm said. The second new gum is YOOFORIC PILLOW TALK, infused with a blend of hemp extract, melatonin, L-Tryptophan and Vitamin B3. It is aimed at helping a person calm their mind for a relaxed night of sleep.

Inc (NASDAQ:HUGE) () announced Monday that a Phase 1 study of ultramicronized palmitoylethanolamide (PEA), or FSD201, found the drug “to be safe and well tolerated.” The company noted that mild and self-limiting side effects were reported and were deemed unlikely to be related to the study of the anti-inflammatory drug. In addition, there were no abnormal laboratory findings or ECGs observed during the study and no serious adverse events were reported. And no subjects withdrew due to an adverse event and all eligible subjects completed all doses.  CEO Dr Raza Bokhari said the company will submit the top-line results from the randomized, double-blind, placebo-controlled study for publication in a peer-reviewed journal and to launch a Phase 2a proof-of-concept trial of FSD201 for the treatment of COVID-19.

Technology Inc () (OTCQB:NTTCF), a cryptocurrency payments company,  announced Friday that it received an industry-leading US$1.4 billion credit facility to fund merchant settlements, thus making it easier to hold crypto positions. The company negotiated the deal — which it said is the largest credit line ever granted to a cryptocurrency payments company —  in order to increase the potential of cryptocurrency as a means of exchange. By using the facility to pay merchant settlements (read: the means by which merchants are paid by consumers) believes it can eliminate the volatility risk that makes holding crypto positions more difficult.

Ltd () () has reported more encouraging drill results from its…